Scientists test new drug to Fine-Tune blood clotting treatments

NCT ID NCT06517563

Summary

This early-stage study aims to understand how a new investigational drug, VMX-C001, interacts with standard blood thinners (anticoagulants) in the body. It involves 16 healthy volunteers who will receive the new drug alongside common medications like heparin and rivaroxaban. Researchers will measure changes in various blood clotting tests to see how VMX-C001 affects the activity of these other drugs.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COAGULATION DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • ICON

    Groningen, 9728 NZ, Netherlands

Conditions

Explore the condition pages connected to this study.